Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics

Journal of Medicinal Chemistry

Volumn 58, Issue 20, 2015, Pages 7959-7971

  Garcia Barrantes, Pedro M ^a   Cho, Hyekyung P ^a   Niswender, Colleen M ^a   Byers, Frank W ^a   Locuson, Charles W ^a   Blobaum, Anna L ^a   Xiang, Zixiu ^a   Rook, Jerri M ^a   Conn, P Jeffrey ^a   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR AGONIST; MUTANT PROTEIN; N (3 CHLORO 4 (1,3 DIOXOISOINDOLIN 2 YL)PHENYL) 3 METHYLFURAN 2 CARBOXAMIDE; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; EC50; ELECTROPHYSIOLOGY; GENE; GENE MUTATION; GRM1 GENE; HIPPOCAMPAL CA3 REGION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; WILD TYPE; AGONISTS; ANIMAL; CHEMICALLY INDUCED; CONFORMATION; DRUG EFFECTS; EPILEPSY; GENETICS; HALF LIFE TIME; METABOLISM; SYNTHESIS;

ANIMALS; CENTRAL NERVOUS SYSTEM; EPILEPSY; GABA AGONISTS; GABA MODULATORS; HALF-LIFE; HUMANS; MOLECULAR CONFORMATION; RATS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84945359287     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00727     Document Type: Article

References (46)

1. Conn, P. J.; Pin, J.-P. Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237 10.1146/annurev.pharmtox.37.1.205
2. Owen, D. R. Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu1) ACS Chem. Neurosci. 2011, 2, 394-401 10.1021/cn2000124
3. Urwyler, S. Allosteric modulation of Family C G-Protein-Coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63, 59-126 10.1124/pr.109.002501
4. Emery, A. C.; DiRaddo, J. O.; Miller, E.; Hathaway, H. A.; Pshenichkin, S.; Takoudjou, G. R.; Grajkowska, E.; Yasuda, R. P.; Wolfe, B. B.; Wroblewski, J. T. Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediate signaling Mol. Pharmacol. 2012, 82, 291-301 10.1124/mol.112.078444
5. Engers, D. W.; Lindsley, C. W. Allosteric modulation of Class C GPCRs: A novel approach for the treatment of CNS disorders Drug Discovery Today: Technol. 2013, 10, e269-e276 10.1016/j.ddtec.2012.10.007
6. Lindsley, C. W. 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug discovery targeting allosteric sites J. Med. Chem. 2014, 57, 7485-7498 10.1021/jm5011786
7. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for the treatment of CNS disorders Nat. Rev. Drug Discovery 2014, 13, 692-708 10.1038/nrd4308
8. Wenthur, C. J.; Gentry, P. R.; Mathews, T. P.; Lindsley, C. W. Drugs for allosteric sites on receptors Annu. Rev. Pharmacol. Toxicol. 2014, 54, 165-184 10.1146/annurev-pharmtox-010611-134525
9. Conn, P. J.; Lindsley, C. W.; Jones, C. Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31 10.1016/j.tips.2008.10.006
10. Stauffer, S. R. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5) ACS Chem. Neurosci. 2011, 2, 450-470 10.1021/cn2000519
11. 5) positive allosteric modulators (PAMs) for the treatment of schizophrenia: An historical perspective and a review of the patent literature Pharm. Pat. Anal. 2013, 2, 93-108 10.4155/ppa.12.82
12. 5 ACS Chem. Neurosci. 2011, 2, 411-432 10.1021/cn2000266
13. Knoflach, F.; Mutel, V.; Jolidon, S.; Kew, J. N.; Malherbe, P.; Vieira, E.; Wichmann, J.; Kemp, J. A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 13402-13407 10.1073/pnas.231358298
14. Vieira, E.; Huwyler, J.; Jolidon, S.; Knoflach, F.; Mutel, V.; Wichmann, J. 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl and (2H-tertazol-5-yl)-amides as potent, orally available mGlu1 enhancers Bioorg. Med. Chem. Lett. 2005, 15, 4628-4631 10.1016/j.bmcl.2005.05.135
15. Vieira, E.; Huwyler, J.; Jolidon, S.; Knoflach, F.; Mutel, V.; Wichmann, J. Fluorinated 9H-Xanthene-9-carboxylic acid oxazol-2-yl amides as potent, orally available mGlu1 enhancers Bioorg. Med. Chem. Lett. 2009, 19, 1666-1669 10.1016/j.bmcl.2009.01.108
16. Hemstapat, K.; dePaulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators Mol. Pharmacol. 2006, 70, 616-626 10.1124/mol.105.021857
17. Fazio, F.; Notartomaso, S.; Aronica, E.; Storto, M.; Battaglia, G.; Vieira, E.; Gatti, S.; Bruno, V.; Biagioni, F.; Gradini, R.; Nicoletti, F.; Di Marco, R. Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autoptic cerebellear samples from patients with multiple sclerosis Neuropharmacology 2008, 55, 491-499 10.1016/j.neuropharm.2008.06.066
18. Ngomba, R. T.; Santolini, I.; Biagioni, F.; Molinaro, G.; Simonyi, A.; van Rijn, C. M.; D'Amore, V.; Mastroiacovo, F.; Olivieri, G.; Gradini, R.; Ferraguti, F.; Battaglia, G.; Bruno, V.; Puliti, A.; van Luijtelaar, G.; Nicoletti, F. Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in in the WAG/Rij model of absence epilepsy Neuropharmacology 2011, 60, 1281-1291 10.1016/j.neuropharm.2011.01.007
19. D'Amore, V.; Santolini, I.; Celli, R.; Lionetto, L.; De Fusco, A.; Simmaco, M.; van Rijn, C. M.; Vieira, E.; Stauffer, S. R.; Conn, P. J.; Bosco, P.; Nicoletti, F.; van Luijtelaar, G.; Ngomba, R. T. Head-to-head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats Neuropharmacology 2014, 85, 91-103 10.1016/j.neuropharm.2014.05.005
20. Notartomaso, S.; Zappulla, C.; Biagioni, F.; Cannella, M.; Bucci, D.; Mascio, G.; Scarselli, P.; Fazio, F.; Weisz, F.; Lionetto, L.; Simmaco, M.; Gradini, R.; Battaglia, G.; Signore, M.; Puliti, A.; Nicoletti, F. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1 Mol. Brain 2013, 6, 48 10.1186/1756-6606-6-48
21. Frank, R. A. W.; McRae, A. F.; Pocklington, A. J.; van de Lagemaat, L. N.; Navarro, P.; Croning, M. D. R.; Komiyama, N. H.; Bradley, S. J.; Challiss, R. A. J.; Armstrong, J. D.; Finn, R. D.; Malloy, M. P.; MacLean, A. W.; Harris, S. E.; Starr, J. M.; Bhaskar, S. S.; Howard, E. K.; Hunt, S. E.; Coffey, A. J.; Ranganath, V.; Deloukas, P.; Rogers, J.; Muir, W. J.; Deary, I. J.; Blackwood, D. H.; Visscher, P. M.; Grant, S. G. N. Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder PLoS One 2011, 6, e19011 10.1371/journal.pone.0019011
22. Ayoub, M. A.; Angelicheva, D.; Vile, D.; Chandler, D.; Morar, B.; Cavanaugh, J. A.; Visscher, P. M.; Jablensky, A.; Pfleger, K. D. G.; Kalaydjieva, L. Deleterious GRM1 mutations in schizophrenia PLoS One 2012, 7, e32849 10.1371/journal.pone.0032849
23. 1 receptors derived from deleterious GRM1 mutations found in schizophrenics ACS Chem. Biol. 2014, 9, 2334-2346 10.1021/cb500560h
24. Cho, H. P.; Engers, D. W.; Venable, D. F.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J.; Emmitte, K. A.; Rodriguez, A. L. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between rat and human receptors' ACS Chem. Neurosci. 2014, 5, 597-610 10.1021/cn5000343
25. Sharma, S.; Kedrowski, J.; Rook, J. M.; Smith, J. M.; Jones, C. K.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Discovery of molecular switches that modulate modes of mGluR5 pharmacology in vitro and in vivo within a series of functionalized 5-(phenylethynyl)pyrimidines J. Med. Chem. 2009, 52, 4103-4106 10.1021/jm900654c
26. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. 'Molecular switches' on allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2410 10.1021/bi200129s
27. Menniti, F. S.; Lindsley, C. W.; Conn, P. J.; Pandit, J.; Zagouras, P.; Volkmann, R. A. Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic networks Curr. Top. Med. Chem. 2013, 13, 26-54 10.2174/1568026611313010005
28. Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. Allosteric modulation of 7 transmembrane spanning receptors: Theory, practice and opportunities for CNS drug discovery J. Med. Chem. 2012, 55, 1445-1464 10.1021/jm201139r
29. 4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents ACS Chem. Neurosci. 2014, 5, 920-942 10.1021/cn500128b
30. 5 positive allosteric modulator clinical candidate targeting schizophrenia ACS Med. Chem. Lett. 2015, 6, 716-720 10.1021/acsmedchemlett.5b00181
31. 5 modulation of NMDAR currents Neuron 2015, 86, 1029-1040 10.1016/j.neuron.2015.03.063
32. Iderberg, H.; Maslava, N.; Thompson, A. D.; Bubser, M.; Niswender, C. M.; Hopkins, C. R.; Lindsley, C. W.; Conn, P. J.; Jones, C. K.; Cenci, M. A. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l -DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist Neuropharmacology 2015, 95, 121-129 10.1016/j.neuropharm.2015.02.023
33. Rook, J. M.; Tantawy, M. N.; Ansari, M. S.; Felts, A. S.; Stauffer, S. R.; Emmitte, K. A.; Kessler, R. M.; Niswender, C. M.; Daniels, J. S.; Jones, C. K.; Lindsley, C. W.; Conn, P. J. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles Neuropsychopharmacology 2015, 40, 755-765 10.1038/npp.2014.245
34. Morris, L. C.; Nance, K. D.; Gentry, P. R.; Days, E. L.; Weaver, C. D.; Niswender, C. M.; Thompson, A. D.; Jones, C. K.; Locuson, C. W.; Morrison, R. D.; Daniels, J. S.; Niswender, K. D.; Lindsley, C. W. Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant GLP-1 positive allosteric modulator (PAM) J. Med. Chem. 2014, 57, 10192-10197 10.1021/jm501375c
35. 4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100 Neuropsychopharmacology 2014, 39, 1578-1593 10.1038/npp.2014.2
36. 2A antagonist in preclinical rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 2012, 340, 404-421 10.1124/jpet.111.187443
37. Williams, R.; Zhou, Y.; Niswender, C. M.; Luo, Q.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Re-exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4 ACS Chem. Neurosci. 2010, 1, 411-419 10.1021/cn9000318
38. 4) with oral efficacy in an anti-parkinsonian animal model J. Med. Chem. 2011, 54, 7639-7647 10.1021/jm200956q
39. 14C]pomalidomide in humans following oral administration Cancer Chemother. Pharmacol. 2013, 71, 489-501 10.1007/s00280-012-2040-6
40. Barbosa, M. L. D.; Ramos, T. J. F.; de Arantes, A. C. S.; Martins, M. A.; e Silva, P. M. R.; Barreiro, E. J.; Lima, L. M. Synthesis and pharmacological evaluation of novel phenyl sulfonamide derivatives designed as modulators of pulmonary inflammatory response Molecules 2012, 17, 14651-14672 10.3390/molecules171214651
41. Tizzano, J. P.; Griffey, K. I.; Schoepp, D. D. Receptor subtypes linked to metabotropic glutamate receptor agonist-mdeiated limbic seizures in mice Ann. N. Y. Acad. Sci. 1995, 765, 230-241 10.1111/j.1749-6632.1995.tb16579.x
42. Wong, R. K.; Bianchi, R.; Chuang, S. C.; Merlin, L. R. Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGlu1 and mGlu5 and implications for antieplileptic drug design Epilepsy Curr. 2005, 5, 63-74 10.1111/j.1535-7597.2005.05207.x
43. 5 determine differences in in vivo activity Biol. Psychiatry 2013, 73, 501-509 10.1016/j.biopsych.2012.09.012
44. 5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254) J. Med. Chem. 2013, 56, 7976-7996 10.1021/jm401028t
45. 5 in regulating CNS function Mol. Pharmacol. 2012, 81, 120-133 10.1124/mol.111.075184
46. Bridges, T. M.; Rook, J. M.; Noetzel, M. J.; Morrison, R. D.; Zhou, Y.; Gogliotti, R. D.; Vinson, P. N.; Jones, C. K.; Niswender, C. M.; Lindsley, C. W.; Stauffer, S. R.; Conn, P. J.; Daniels, J. S. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizures in rats involving a receptor agonism-dependent mechanism Drug Metab. Dispos. 2013, 41, 1703-1714 10.1124/dmd.113.052084